Portal de Periódicos da CAPES

Pertuzumab: new hope for patients with HER2-positive breast cancer

2012; Elsevier BV; Volume: 24; Issue: 2 Linguagem: Inglês

10.1093/annonc/mds328

1569-8041

Marta Capelán, Lina Pugliano, Evandro de Azambuja, Ivana Babič Božović, Kamal S. Saini, Christos Sotiriou, Sherene Loi, Martine Piccart,

Peptidase Inhibition and Analysis

Human epidermal growth factor receptor 2 (HER2) overexpression is detected in approximately 15% to 20% of all breast cancers (BCs). A revolutionary change in the prognosis of this subgroup of patients has occurred since trastuzumab therapy was introduced into daily clinical practice. However, because trastuzumab resistance is common, new molecules with complementary and/or synergistic mechanisms of action have been developed. Pertuzumab is a new anti-HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers.